Lauren T. Adrian

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu et al. · Cancer Cell · 2009 · 1.2K citations · Full text

Hematological Malignancy, Tumor Biology, Chronic Myeloid Leukemia +9

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Jamshid S. Khorashad, Todd W. Kelley, Philippe Szankasi et al. · Blood · 2012 · 218 citations · Full text

The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile

Christopher A. Eide, Lauren T. Adrian, Jeffrey Tyner et al. · Cancer Research · 2011 · 118 citations · Full text

Acute dasatinib exposure commits Bcr-Abl–dependent cells to apoptosis

Jennifer L. Snead, Thomas O’Hare, Lauren T. Adrian et al. · Blood · 2009 · 59 citations · Full text

The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Thomas O’Hare, Matthew S. Zabriskie, Christopher A. Eide et al. · Blood · 2011 · 47 citations · Full text